Ariad Pharmaceuticals: Substantiating Its Solid Scientific Fundamentals and the Value of Its Strategy

Ariad Pharmaceuticals (ARIA): Good news from the U.S. Food and Drug Administration (FDA) affirmed that the agency accepted for review Ariad’s New Drug Application (NDA) for its investigational oral anaplastic lymphoma kinase (ALK) inhibitor, brigatinib for patients with metastatic ALK-positive (ALK+) non-small cell lung cancer (NSCLC) who have progressed after being treated with crizotinib. The NDA submission includes clinical data from its Phase 1/2 and pivotal Phase 2 ALTA trials of brigatinib.

The FDA granted ARIAD’s request for Priority Review and set an action date . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.